review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Ralph A. DeFronzo | Q58689309 |
Eleuterio Ferrannini | Q59193801 | ||
P2860 | cites work | Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes | Q22250887 |
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults | Q22250906 | ||
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review | Q22253058 | ||
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus | Q24243196 | ||
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats | Q24563606 | ||
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies | Q24608301 | ||
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study | Q24652963 | ||
Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease | Q26866392 | ||
Residual macrovascular risk in 2013: what have we learned? | Q26996039 | ||
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
The target of metformin in type 2 diabetes | Q28249761 | ||
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q28254549 | ||
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Q28281870 | ||
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes | Q28282265 | ||
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study | Q28293505 | ||
Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes | Q28295311 | ||
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study | Q30700439 | ||
Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial | Q30840447 | ||
Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo | Q36635727 | ||
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis | Q36649277 | ||
Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease | Q36667186 | ||
Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes | Q36730207 | ||
Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease | Q36782688 | ||
Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. | Q36792608 | ||
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies | Q36807402 | ||
Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). | Q36914416 | ||
Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors. | Q36945300 | ||
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). | Q37106424 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes | Q37193454 | ||
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 | ||
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates | Q37251096 | ||
The incretin system and its role in type 2 diabetes mellitus | Q37266863 | ||
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. | Q37322877 | ||
Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? | Q37395298 | ||
Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study | Q37403220 | ||
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors | Q37505281 | ||
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? | Q37535457 | ||
In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion | Q37577126 | ||
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? | Q37792839 | ||
Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us? | Q37803259 | ||
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review | Q37813161 | ||
Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies | Q37824904 | ||
Pathophysiology of prediabetes | Q37833737 | ||
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. | Q37878715 | ||
Preservation of β-cell function: the key to diabetes prevention | Q37893344 | ||
Reducing cardiovascular disease risk in patients with type 2 diabetes and concomitant macrovascular disease: can insulin be too much of a good thing? | Q37898749 | ||
The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury | Q37926558 | ||
Incretin-based therapies for treatment of postprandial dyslipidemia in insulin-resistant states | Q37962246 | ||
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials | Q37971194 | ||
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. | Q37981884 | ||
Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. | Q38031093 | ||
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial | Q38085534 | ||
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). | Q31120403 | ||
Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria | Q31931889 | ||
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 | ||
Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study | Q33487709 | ||
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study | Q33508039 | ||
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes | Q33562235 | ||
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) | Q33764951 | ||
An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. | Q33786150 | ||
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis | Q33873053 | ||
Hypoglycemia, diabetes, and cardiovascular events | Q33873251 | ||
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 | ||
Diabetes mellitus, fasting glucose, and risk of cause-specific death | Q33945937 | ||
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis | Q34031108 | ||
DPP-4 inhibitors and lipids: systematic review and meta-analysis | Q34116689 | ||
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data | Q34128612 | ||
Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention--a retrospective nationwide cohort study | Q34158078 | ||
Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program | Q34195798 | ||
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study | Q34257350 | ||
Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach | Q34294997 | ||
Thiazolidinediones | Q34346862 | ||
Results of a reevaluation of cardiovascular outcomes in the RECORD trial | Q34360464 | ||
A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study | Q34421981 | ||
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database | Q34422144 | ||
Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes | Q34424907 | ||
Insulinotropic meglitinide analogues | Q34453173 | ||
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes | Q34453811 | ||
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. | Q34509910 | ||
Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta | Q34537980 | ||
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance | Q34577169 | ||
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis | Q34585893 | ||
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial | Q34593046 | ||
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 | ||
Insulin resistance, insulin response, and obesity as indicators of metabolic risk | Q43682653 | ||
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study | Q43687453 | ||
Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide | Q43834028 | ||
Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians | Q43850960 | ||
Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study | Q44043328 | ||
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients | Q44110180 | ||
Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. | Q44117925 | ||
Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes | Q44136140 | ||
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials | Q44143356 | ||
Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart | Q44153403 | ||
Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study | Q44155565 | ||
Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study | Q44155702 | ||
Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics | Q44183858 | ||
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality | Q44205053 | ||
Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes | Q44231053 | ||
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study | Q34623719 | ||
Metformin use and mortality among patients with diabetes and atherothrombosis | Q34625337 | ||
Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction | Q34633720 | ||
Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study | Q34644993 | ||
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes | Q34692143 | ||
Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study | Q34720231 | ||
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
Intensive glucose control and macrovascular outcomes in type 2 diabetes. | Q34995674 | ||
Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies | Q34996877 | ||
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people | Q35004093 | ||
Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality | Q35012749 | ||
The Look AHEAD Trial: A Review and Discussion Of Its Outcomes | Q35116229 | ||
Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therap | Q35178857 | ||
Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes | Q35179865 | ||
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes | Q35179964 | ||
Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study | Q35235773 | ||
The role of gut hormones in glucose homeostasis | Q35251016 | ||
Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus | Q35345865 | ||
Thiazolidinediones, Peripheral Edema, and Type 2 Diabetes: Incidence, Pathophysiology, and Clinical Implications | Q35570243 | ||
Dapagliflozin lowers plasma glucose concentration and improves β-cell function | Q35578244 | ||
Insulin resistance and the effects of thiazolidinediones on cardiac metabolism | Q35609203 | ||
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus | Q35751679 | ||
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme | Q35777074 | ||
Extrapancreatic effects of GIP and GLP-1. | Q36012504 | ||
The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit | Q36261162 | ||
Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial | Q36297833 | ||
Mechanisms of beta-cell death in type 2 diabetes. | Q36321520 | ||
Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review | Q36396145 | ||
The place of sulfonylureas in the therapy for type 2 diabetes mellitus | Q36456659 | ||
Cardiovascular biology of the incretin system | Q36484283 | ||
The effects of thiazolidinediones on blood pressure levels - a systematic review | Q36545395 | ||
Impairment of myocardial protection in type 2 diabetic patients | Q44306774 | ||
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors | Q44442589 | ||
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin | Q44448309 | ||
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium | Q44512663 | ||
Thiazolidinediones and blood lipids in type 2 diabetes | Q44542266 | ||
Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes | Q44620317 | ||
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study | Q44686996 | ||
Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus | Q44759159 | ||
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study | Q44802551 | ||
Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes | Q44882775 | ||
Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes | Q44909522 | ||
Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention | Q44912661 | ||
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. | Q44924385 | ||
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus | Q45036323 | ||
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 | ||
Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 | ||
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
Metabolic syndrome: evaluation of pathological and therapeutic outcomes | Q45230909 | ||
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone | Q45329104 | ||
CNTO736, a novel glucagon-like peptide-1 receptor agonist, ameliorates insulin resistance and inhibits very low-density lipoprotein production in high-fat-fed mice | Q45810167 | ||
Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control | Q46018332 | ||
Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. | Q46024732 | ||
Chronic insulin administration elevates blood pressure in rats | Q46074981 | ||
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes | Q46226028 | ||
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study | Q46481435 | ||
Dose-response effect of elevated plasma free fatty acid on insulin signaling | Q46513253 | ||
Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). | Q46552257 | ||
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 | ||
Effect of a multifactorial intervention on mortality in type 2 diabetes | Q46767642 | ||
Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study | Q46773983 | ||
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure | Q46817496 | ||
Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes | Q46819106 | ||
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans | Q46919674 | ||
Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial | Q46936072 | ||
Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin | Q46981921 | ||
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Q47333592 | ||
The disposition index does not reflect β-cell function in IGT subjects treated with pioglitazone | Q48271768 | ||
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. | Q50219055 | ||
Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. | Q50590197 | ||
Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. | Q50798695 | ||
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. | Q51061297 | ||
Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. | Q51325737 | ||
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. | Q51334840 | ||
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. | Q51368060 | ||
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. | Q51381989 | ||
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. | Q51468950 | ||
The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population. | Q51472360 | ||
Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. | Q51479687 | ||
Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus | Q38085691 | ||
Effects of dapagliflozin on cardiovascular risk factors | Q38113098 | ||
Molecular biology of atherosclerosis | Q38125279 | ||
Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications | Q38197344 | ||
Canagliflozin: a review of its use in patients with type 2 diabetes mellitus | Q38212007 | ||
Mortality risk among sulfonylureas: a systematic review and network meta-analysis | Q38281461 | ||
A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans | Q38490894 | ||
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. | Q39030156 | ||
Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus | Q39451977 | ||
Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study | Q39518005 | ||
Is insulin atherogenic? | Q39637369 | ||
Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. | Q39648063 | ||
Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study | Q39839307 | ||
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules | Q39896648 | ||
Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study | Q39942752 | ||
Glucagon-like peptide-1 attenuates tumour necrosis factor-alpha-mediated induction of plasminogen [corrected] activator inhibitor-1 expression | Q40027585 | ||
Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits | Q40046793 | ||
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus | Q40102509 | ||
Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia--13-year study | Q41450119 | ||
Effect of insulin on growth of cultured human arterial smooth muscle cells | Q41615238 | ||
Insulin resistance in the vasculature | Q41856477 | ||
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice | Q41984767 | ||
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes | Q42450726 | ||
Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients | Q42485940 | ||
Basal insulin and cardiovascular and other outcomes in dysglycemia | Q42507791 | ||
In vivo effect of insulin on intracellular calcium concentrations: relation to insulin resistance | Q42527358 | ||
Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression | Q42832873 | ||
Severe hypoglycemia and risks of vascular events and death | Q42868535 | ||
Dipeptidyl Peptidase IV Inhibition Alters the Hemodynamic Response to Angiotensin-Converting Enzyme Inhibition in Humans With the Metabolic Syndrome | Q42949053 | ||
Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus | Q43014666 | ||
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population | Q43046359 | ||
The stunned beta cell: a brief history | Q43073326 | ||
Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion | Q43142618 | ||
Exenatide versus glibenclamide in patients with diabetes | Q43164036 | ||
Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study | Q43181601 | ||
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure | Q43191785 | ||
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients | Q43218473 | ||
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice | Q43231241 | ||
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes | Q43236097 | ||
Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue | Q43237616 | ||
Three-year efficacy of complex insulin regimens in type 2 diabetes | Q43256453 | ||
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. | Q43409321 | ||
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury | Q43574002 | ||
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone | Q43584208 | ||
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death | Q43596005 | ||
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. | Q51486013 | ||
The effect of pioglitazone on the liver: role of adiponectin. | Q51488911 | ||
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. | Q51495360 | ||
Treatment of familial hypertriglyceridaemia with acarbose. | Q51550714 | ||
Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. | Q51554500 | ||
Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmö, Sweden. | Q51556160 | ||
Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. | Q51564567 | ||
Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. | Q51573561 | ||
Insulin resistance and coronary artery disease. | Q51578743 | ||
Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. | Q51581413 | ||
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 | ||
Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. | Q51600420 | ||
Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. | Q51610700 | ||
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. | Q51612089 | ||
Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? | Q51615482 | ||
Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo. | Q51625510 | ||
Relationship of Glucose Tolerance and Plasma Insulin to the Incidence of Coronary Heart Disease: Results from Two Population Studies in Finland | Q51662797 | ||
Relation of plaque lipid composition and morphology to the stability of human aortic plaques. | Q52526775 | ||
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. | Q52876034 | ||
Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. | Q52961670 | ||
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria | Q53998038 | ||
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. | Q54243732 | ||
Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. | Q54539426 | ||
Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs | Q57300672 | ||
Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age | Q57413995 | ||
Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: a European cross-sectional study | Q57563912 | ||
Sulfonylurea and glinide reduce insulin content, functional expression of KATP channels, and accelerate apoptotic β-cell death in the chronic phase | Q57591412 | ||
Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study | Q57689262 | ||
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction | Q58447894 | ||
Insulin Sensitivity, Vascular Reactivity, and Clamp-Induced Vasodilatation in Essential Hypertension | Q59297471 | ||
P433 | issue | 34 | |
P921 | main subject | cardiovascular disease | Q389735 |
type 2 diabetes | Q3025883 | ||
P304 | page(s) | 2288-2296 | |
P577 | publication date | 2015-06-10 | |
P1433 | published in | European Heart Journal | Q2286839 |
P1476 | title | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes | |
P478 | volume | 36 |
Q94521883 | A PKB-SPEG signaling nexus links insulin resistance with diabetic cardiomyopathy by regulating calcium homeostasis |
Q46078298 | A pilot study on clinical pharmacokinetics and preclinical pharmacodynamics of (+)-epicatechin on cardiometabolic endpoints |
Q92167256 | A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes |
Q93143143 | A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial |
Q55516148 | Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy. |
Q47157747 | Alteration of Vascular Responsiveness to Uridine Adenosine Tetraphosphate in Aortas Isolated from Male Diabetic Otsuka Long-Evans Tokushima Fatty Rats: The Involvement of Prostanoids. |
Q38639922 | An overview of new GLP-1 receptor agonists for type 2 diabetes |
Q38877104 | Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes. |
Q53568958 | Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. |
Q88312494 | Antihyperglycemic Medications and Cardiovascular Risk Reduction |
Q61451341 | Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 |
Q89478072 | Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map |
Q51057720 | Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. |
Q92860682 | Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins? |
Q38702260 | Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists |
Q38767511 | Cardiometabolic crosstalk in obesity-associated arterial hypertension |
Q47297477 | Cardioprotective anti-hyperglycaemic medications: a review of clinical trials |
Q55053753 | Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. |
Q38683079 | Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting |
Q38857056 | Cardiovascular effects of anti-diabetes drugs |
Q26741082 | Cardiovascular safety of anti-diabetic drugs |
Q39226058 | Cardiovascular safety of liraglutide for the treatment of type 2 diabetes |
Q39735496 | Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles |
Q37620904 | Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes |
Q40808660 | Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study |
Q30238519 | Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management |
Q37011769 | Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations |
Q57813255 | Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study |
Q26740253 | Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? |
Q54993721 | Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea. |
Q33727891 | Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis |
Q39409421 | Considerations and treatment options for patients with comorbid atrial fibrillation and diabetes mellitus |
Q39393549 | Coronary microvascular dysfunction in diabetes mellitus |
Q28066006 | Current perspectives on cardiovascular outcome trials in diabetes |
Q47148482 | DPP-4 inhibition with linagliptin ameliorates the progression of premature aging in klotho-/- mice |
Q36338382 | DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety |
Q93006261 | Dapagliflozin: A Review in Type 2 Diabetes |
Q58707336 | Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data |
Q92821935 | Diabetes attenuated age-related aortic root dilatation in end-stage renal disease patients receiving peritoneal dialysis |
Q49833824 | Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms |
Q38599145 | Dipeptidyl peptidase-4 inhibitor use in patients with type 2 diabetes and cardiovascular disease or risk factors |
Q92544171 | Dose distribution and up-titration patterns of metformin monotherapy in patients with type 2 diabetes |
Q40113914 | Dulaglutide (LY-2189265) for the treatment of type 2 diabetes |
Q60044715 | Evaluating the Diabetes-Cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney's 'diabetes hotspot' and the establishment of a novel model of care |
Q48042047 | Functional interplay between LXR and AMPKα inhibits atherosclerosis in apoE deficient mice - A new anti-atherogenic strategy. |
Q92706749 | GLP-1-based therapies to boost autophagy in cardiometabolic patients: From experimental evidence to clinical trials |
Q26738580 | Glucagon and heart in type 2 diabetes: new perspectives |
Q91023787 | Highly Selective and Potent Human β-Secretase 2 (BACE2) Inhibitors against Type 2 Diabetes: Design, Synthesis, X-ray Structure and Structure-Activity Relationship Studies |
Q33625568 | Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes |
Q39418202 | Impact of the use of anti-diabetic drugs on survival of diabetic dialysis patients: a 5-year retrospective cohort study in Taiwan |
Q38798623 | Implications of the EMPA-REG Trial for Clinical Care and Research |
Q38937735 | Investigational glucagon-like peptide-1 agonists for the treatment of obesity |
Q58127020 | Liraglutide Treatment Reduces Endothelial Endoplasmic Reticulum Stress and Insulin Resistance in Patients With Diabetes Mellitus |
Q39245449 | Metabolic Recovery of the Failing Heart: Emerging Therapeutic Options. |
Q54977501 | Metformin and AMP Kinase Activation Increase Expression of the Sterol Transporters ABCG5/8 (ATP-Binding Cassette Transporter G5/G8) With Potential Antiatherogenic Consequences. |
Q90128752 | Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation |
Q91810107 | Moderate weight change following diabetes diagnosis and 10 year incidence of cardiovascular disease and mortality |
Q57822737 | Modern Sulfonylureas Strike Back - Exploring the Freedom of Flexibility |
Q64926407 | PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. |
Q52603694 | Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c. |
Q47696671 | Pharmacological management of type 2 diabetes: what's new in 2017? |
Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
Q38952882 | Progressing From Metformin to Sulfonylureas or Meglitinides |
Q46230278 | Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. |
Q36531636 | Puerarin Improves Diabetic Aorta Injury by Inhibiting NADPH Oxidase-Derived Oxidative Stress in STZ-Induced Diabetic Rats |
Q50053976 | Pulse pressure and diabetes treatments: Blood pressure and pulse pressure difference among glucose lowering modality groups in type 2 diabetes. |
Q38651194 | Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data |
Q39035951 | Renal, metabolic and cardiovascular considerations of SGLT2 inhibition |
Q33696974 | SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease |
Q89052452 | SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes? |
Q38662950 | Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. |
Q28072765 | Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects |
Q38783203 | Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes |
Q38827756 | Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus |
Q90726031 | Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus |
Q54444751 | Syncope and sudden cardiac death: some answers to clinical challenges. |
Q33732583 | The Relationship between Increases in Morning Spot Urinary Glucose Excretion and Decreases in HbA1C in Patients with Type 2 Diabetes After Taking an SGLT2 Inhibitor: A Retrospective, Longitudinal Study. |
Q64248091 | The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm |
Q55024341 | The association study of high-sensitivity C-reactive protein, pentraxin 3, nitrotyrosine, and insulin dose in patients with insulin-treated type 2 diabetes mellitus. |
Q33700894 | The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. |
Q33805518 | The regulatory role of DPP4 in atherosclerotic disease. |
Q58610751 | Trans-repression of NFκB pathway mediated by PPARγ improves vascular endothelium insulin resistance |
Q28073342 | Update on the treatment of type 2 diabetes mellitus |